SCHEMBL4399166

SCHEMBL4399166

COc1cc(OC)c(F)c(C(=O)C(=O)O)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
RAB9A P51151 2/20 0.42
HTT P42858 2/20 0.42
MAPK1 P28482 1/20 0.42
CYP3A4 P08684 3/20 0.41
CA12 O43570 3/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA7 P43166 3/20 0.39
CA9 Q16790 3/20 0.39
CA14 Q9ULX7 3/20 0.39
CA4 P22748 2/20 0.38
CA6 P23280 2/20 0.38
CA3 P07451 1/20 0.38
PKM P14618 1/20 0.38
CA5A P35218 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
TP53 P04637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TPMT P51580 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5382289 0.89 HTT (0.41) LMNARAB9AHTTMAPK1CYP3A4
SCHEMBL4398646 0.88 TSHR (0.45) RAB9AMAPK1CYP3A4TP53KMT2A
SCHEMBL4405562 0.88 LMNA (0.39) LMNARAB9AHTTMAPK1CYP3A4
SCHEMBL1819165 0.83 CA12 (0.52) LMNARAB9AHTTMAPK1CYP3A4
SCHEMBL4410411 0.81 MEN1 (0.39) LMNARAB9AHTTMAPK1CYP3A4
SCHEMBL28876343 0.81 CYP3A4 (0.44) LMNARAB9AHTTMAPK1CYP3A4
SCHEMBL4403048 0.80 TSHR (0.41) LMNARAB9AHTTMAPK1CYP3A4
SCHEMBL4398521 0.79 TSHR (0.44) LMNARAB9AMAPK1CYP3A4GLA
SCHEMBL4406881 0.79 LMNA (0.46) LMNARAB9AHTTMAPK1CA12
SCHEMBL18131839 0.79 CYP3A4 (0.53) LMNARAB9AHTTMAPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 LMNA 2809/4885RAB9A 3575/4885HTT 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.